Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Investor Presentation (August 2026)
32 slides from Arovella Therapeutics's investor presentation, Aug 12, 2026
Slide 1: Investor Webinar ASX Release
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 ASX Release 12 August 2026 INVESTOR WEBINAR Arovella Therapeutics Ltd (ASX: ALA), a clinical-stage biotechnology company developing an “off-the-shelf” invariant Natural Killer T (iNKT) cell therapy platform, will today host an investor webinar f
Slide 2: Notes to Editors: About Arovella Therapeutics
ASX: ALA Arovella Therapeutics Limited ACN 090 987 250 NOTES TO EDITORS: About Arovella Therapeutics Ltd Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumou
Slide 3: Investor webinar 12 August 2026
ASX:ALA For personal use only Investor webinar 12 August 2026
Slide 4: Disclaimer
Disclaimer 1. The information in this presentation does not constitute personal investment advice. 4. Whilst this presentation is based on information from sources which are considered The presentation is not intended to be comprehensive or provide all information reliable, no representation or warr
Slide 5: Cell Therapy has revolutionised blood cancer treatment
Cell Therapy has revolutionised blood cancer treatment CAR-T therapies have demonstrated curative potential in blood cancers For personal use only Cure Product Approval Year 2025 Revenue CAR-T cells have demonstrated ability to 2022 US$1.9 bil3 cure haematological cancers 2017 US$1.5 bil4 Strong 202
Slide 6: How traditional CAR-T cell therapies work
How traditional CAR-T cell therapies work Effective, but patient-specific, time-intensive and operationally complex T cells = immune cell For personal use only T cells are a common type of immune cell that fight infections and can help fight cancer. T cells from patient ‘reprogrammed’ Collect patien
Slide 7: CAR-T technology challenges ALA's off-the-shelf solution
CAR-T technology challenges ALA’s off-the-shelf Only treats the patient who supplied the T cells solution: Manufacturing & supply For personal use only chain costs high, failures T cell can occur Each manufacturing T cell batch is patient-specific T cells can be compromised by disease T cell Limited
Slide 8: Why invest in Arovella
Why invest in Arovella CAR-iNKT platform designed to support multiple future therapies For personal use only Structurally differentiated next-generation cell therapy Near-term clinical validation Platform scalability Pipeline expansion • FDA IND accepted • Off-the-shelf manufacturing • Blood cancers
Slide 9: Strong Leadership Team
Strong Leadership Team SENIOR MANAGEMENT TEAM For personal use only Dr Nicole van der Weerden Dr Robson Dossa Dr Michelle Ferguson Jacqueline Cumming ACTING CHIEF EXECUTIVE OFFICER VP MANUFACTURING & QUALITY SENIOR DIRECTOR RESEARCH & SENIOR DIRECTOR CLINICAL DEVELOPMENT DEVELOPMENT Drug development
Slide 10: Highlights for CY26
Highlights for CY26 Arovella’s lead, ALA-101, advancing to clinical trials for blood cancers For personal use only US FDA accepted Investigational New Drug application for phase 1 Cash and cash equivalents first-in-human trial of ALA-101 in blood cancers at 30 June, 2026 $14.4 Ethics approval to com
Slide 11: CAR-iNKT cells – a differentiated immune cell
CAR-iNKT cells – a differentiated immune cell Unique biology with potential to overcome core limitations of CAR-T Multiple ways to attack tumours For personal use only ALLOGENEIC WITHOUT GENE EDITING Off-the-shelf solution; no gene editing required (preserves cell fitness) MULTIPLE WAYS TO KILL CANC
Slide 12: Overcoming limitations of existing cell therapies
Overcoming limitations of existing cell therapies CAR-iNKT cells are uniquely positioned for cell therapy applications For personal use only Modality Key Limitations Arovella CAR-iNKT Advantage Autologous CAR-T Relies on fitness of patient’s own T cells Healthy donor cells with better fitness
Slide 13: World-class CAR-iNKT manufacturing platform
World-class CAR-iNKT manufacturing platform Semi-automated process suitable for large-scale and late-phase clinical development For personal use only Arovella Manufacturing Platform Isolate iNKT cells Expand to grow billions of CAR-iNKT cells Collect Healthy Engineer iNKT cells to Vial and freeze Do
Slide 14: One platform: three value-creation pathways
One platform: three value-creation pathways Value creation via three workstreams For personal use only Core platform: healthy-donor iNKT cells + modular CAR backbone + scalable manufacturing Blood cancer validation -> solid-tumour expansion -> autoimmunity expansion CD19+ blood CLDN18.2+ solid CD19+
Slide 15: Manufacturing process highly reproducible
Manufacturing process highly reproducible Consistently produces highly potent drug product Killing of CD19+ Tumour Cells For personal use only Robust CAR-iNKT 100 Process Development scale batch 1 manufacturing platform 80 Process Development scale batch 2 Cytotoxicity (%) delivers consistent and 60
Slide 16: ALA-101 Manufacturing Platform
ALA-101 Manufacturing Platform Batches consistently meet pre-specified release specifications For personal use only >80 Clinical doses per batch at the planned starting dose* >99% iNKT Purity 99.6% mean (range 99.2–100.0%) ~23 Manufacturing duration from donor cells to cryopreserved drug product day
Slide 17: ALA-101 (CD19 CAR-iNKT)
For personal use only ALA-101 (CD19 CAR-iNKT)) A next generation off-the-shelf cell therapy for CD19 expressing cancers 15
Slide 18: ALA-101: an off-the-shelf solution for CD19+ blood cancers
ALA-101: an off-the-shelf solution for CD19+ blood cancers Phase 1 first-in-human study expected to commence next month For personal use only Validated target with potential for FDA IND accepted for indication expansion CD19+ lymphomas and Possibility to expand into autoimmunity if phase 1 ALA-101 (
Slide 19: Potent activity in aggressive tumour model
Potent activity in aggressive tumour model Significantly enhances survival and reduces tumour burden For personal use only Survival of ALA-101-treated mice in Raji lymphoma anti-tumour ALA-101 demonstrates efficacy model robust dose-dependent 100 PBS **** activity in an aggressive ALA-101 (1.7M) ***
Slide 20: Taking ALA-101 into first-in-human trials
Taking ALA-101 into first-in-human trials ALA is progressing towards its ALA-101-001 phase 1 study Expected First patient dosed with ALA-101 For personal use only September 2026 First patient successfully enrolled into the study First patient screened for participation in the study ALA-101 (CD19 CAR
Slide 21: ALA-101-001 Phase 1 study; Blood Cancer
ALA-101-001 Phase 1 study; Blood Cancer Study population Adults with relapsed/refractory NHL (DLBCL • FL • MZL • MCL) CD19-positive B cell cancers Leukaemia (CLL • HCL) Patient journey For personal use only 1. Screening 2. Lymphodepletion 3. ALA-101 infusion 4. On-study follow-up 5. Long-term follow
Slide 22: The autoimmune opportunity for ALA-101
The autoimmune opportunity for ALA-101 CD19 cell therapy is emerging as a potential new approach to treat autoimmune disease For personal use only ALA-101 clinical trial The problem in blood cancers Serious autoimmune diseases such as lupus, myositis, stiff person syndrome, generalized myasthenia gr
Slide 23: ALA-105 (CLDN18.2 CAR-iNKT)
For personal use only ALA-105 (CLDN18.2 CAR-iNKT) A clinically validated target that is expressed in several solid tumour types 21
Slide 24: An off-the-shelf solution for solid tumours
An off-the-shelf solution for solid tumours With ALA’s proprietary cytokine armouring For personal use only Validated target with high unmet need Novel, proprietary Potential to target a broad range of cancers CLDN18.2-targeting CAR ALA-105 (CLDN18.2 CAR-iNKT) Addresses key CAR-T challenges Effica
Slide 25: Introducing Claudin 18.2 (CLDN18.2)
Introducing Claudin 18.2 (CLDN18.2) A promising solid tumour target For personal use only ALA-105 (CLDN18.2 CAR-iNKT) CLDN18.2 overexpression has been Validated target identified in several First monoclonal antibody approved in 2024; First CAR-T for solid types of cancers tumours approved in China i
Slide 26: Leverage an antibody to create a CLDN18.2-CAR
Leverage an antibody to create a CLDN18.2-CAR Sequence of SPX-101 used to create novel CAR For personal use only ALA-105 (CLDN18.2 CAR-iNKT) Convert antigen binding Incorporate the CAR sequences into an scFv into Arovella’s platform and format into a CAR The CLDN18.2-binding domains of a monoclonal
Slide 27: "Armouring" CAR-iNKT cells
ARMOURING “Armouring” CAR-iNKT cells IL-12-TM (cytokine technology) enhances CAR-iNKT cell activity in solid tumours For personal use only IL-12-TM IL-12-TM (Armouring for Solid Tumours) iNKT cells IL-12-TM IL-12-TM is a modified version of IL-12 Expand more 10x more Superior with a membrane anchor
Slide 28: Arovella's novel CLDN18.2-targeting CAR is highly active
Arovella’s novel CLDN18.2-targeting CAR is highly active Potent cytotoxicity in iNKT cells improved by armouring with IL-12-TM Killing of Gastric and Pancreatic Cancer For personal use only Gastric cancer cells Pancreatic cancer cells CLDN18.2 CAR in iNKT cells ALA-105 (CLDN18.2 CAR-iNKT) * * ** *
Slide 29: Taking ALA-105 to IND filing
Taking ALA-105 to IND filing ALA is progressing nonclinical development of ALA-105 File IND with the FDA For personal use only Complete IND-enabling studies ALA-105 (CLDN18.2 CAR-iNKT) Complete Process Development to manufacture ALA-105 Manufacture GMP CLDN18.2 CAR lentivirus Test CLDN18.2 CAR-iNKT
Slide 30: Summary
Summary FDA-accepted Near-term clinical-stage company milestones For personal use only ALA-101 entering human trials Clinical batch release, site activation, first patient dosing and initial clinical readouts Differentiated cell Multiple expansion therapy platform CAR-iNKT cells combine Arovella’s o
Slide 31: Thank You
ASX:ALA For personal use only Thank You Arovella Therapeutics Email: investor@arovella.com
Slide 32: Appendix - references
Appendix - references 1. https://www.businesswire.com/news/home/20250210311887/en/CAR-T-Cell-Therapy-Market-Industry-Trends-and-Global-Forecasts-to-2035-CD19-and- BCMA-Have-Emerged-as-the-Most-Popular-Target-Antigens---ResearchAndMarkets.com 2. Zinzi et al., 2023 Pharmacological Research - 10.1016/j
Arovella Therapeutics — Investor Presentation (August 2026) on 6ix